Rhenium-188 P 2045

Drug Profile

Rhenium-188 P 2045

Alternative Names: BAY-865284; NeoTide; P2045; Re-188 P 2045; Rh-188 P2045; Rhenium-188 P2045; Tozaride

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Andarix Pharmaceuticals; Tufts University School of Medicine
  • Class Antineoplastics; Heavy metals; Peptides; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Somatostatin receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Lung cancer
  • Preclinical Pancreatic cancer
  • No development reported Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Small-cell-lung-cancer in USA (IV)
  • 02 Jun 2017 Clinical trials in Lung cancer (Diagnosis) before June 2017 (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top